Scientists Develop a Way to Track Donor Bacteria After Fecal Microbiota Transplants
Findings may guide development of next-generation precision therapies
Researchers at the Icahn School of Medicine at Mount Sinai and their collaborators have developed a new technology to track beneficial bacteria after fecal microbiota transplants (FMT). The approach provides a detailed view of how donor microbes take hold and persist in the patients’ gut—not only which bacteria successfully colonized but how they change over time. These insights may guide the design of safer and more effective microbiome-based therapies.
The study was published in the October 22 online issue of Nature Microbiology [DOI: https://doi.org/10.1038/s41564-025-02164-8].
FMT—the transfer of stool from a healthy donor into a patient’s intestine—has been proven highly effective in treating Clostridioides difficile infection and is being explored for other conditions, such as inflammatory bowel disease (IBD) and cancer. Yet it has remained unclear which bacterial strains are responsible for long-term recovery and how they adapt within their new host environment.
The new approach harnesses long-read DNA sequencing, which reads much longer stretches of a microbe’s genetic code than traditional techniques, with a computational method developed at Mount Sinai called LongTrack. Together, they allow scientists to distinguish even closely related bacterial strains and identify each one’s unique genetic “fingerprint.” This enables researchers to follow donor bacteria from the time of transplant through up to five years of adaptation in the patient’s gut.
“We can follow donor bacteria strain by strain with a level of reliability and scalability that wasn’t possible before using approaches that were based on short-read sequencing,” says senior and corresponding author Gang Fang, PhD, Professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai. “It gives us insight into what happens to the hundreds of donor bacteria after fecal transplants, how they adapt to new patients’ gastrointestinal environments, and points the way toward safer, more consistent, and ultimately more precise treatments.”
Using this approach, the team collaborated with study co-author Jeremiah Faith, PhD, Professor of Immunology and Immunotherapy at the Icahn School of Medicine at Mount Sinai. The team analyzed stool samples from FMT donors and recipients treated for C. difficile infection and IBD. Samples collected before and after treatment, including some taken up to five years later, showed that many donor bacteria took hold and persisted in the recipients’ microbiome. Some strains even displayed genetic mutations indicating adaptation to their new hosts, suggesting that different gut environments can shape bacterial evolution from one individual to another, says Dr. Fang.
By pinpointing which bacteria successfully colonize after FMT, the study provides a roadmap for systematically identifying mixtures of beneficial microbes that could be developed as novel microbiome interventions. These could replace or improve upon whole-stool transplants with treatments that are safer, more predictable, and easier to regulate.
“Our findings bring us closer to precision medicine for the microbiome,” says Dr. Fang. “We can now track beneficial bacteria reliably and on a large scale over time, and importantly, understand the genetic mutations involved in their adaptation in the recipients—a key step toward designing treatments that are both effective and consistent.”
Next, the researchers plan to apply the same approach to larger patient cohorts and to additional diseases in which the gut microbiome plays a role, building on previous and future FMT studies across multiple human conditions. They aim to use LongTrack to identify beneficial bacterial strains that could form the basis of next-generation microbial therapeutics.
The paper is titled “Long-read metagenomics for strain tracking after faecal microbiota transplant.”
The study’s authors, as listed in the journal, are Yu Fan, Mi Ni, Varun Aggarwala, Edward A. Mead, Magdalena Ksiezarek, Lei Cao, Michael A. Kamm, Thomas J. Borody, Sudarshan Paramsothy, Nadeem O. Kaakoush, Ari Grinspan, Jeremiah J. Faith, and Gang Fang.
This work was supported by the National Institutes of Health (NIH) under grant number R35 GM139655. See the journal paper for details on conflicts of interest: https://doi.org/10.1038/s41564-025-02164-8.
About the Icahn School of Medicine at Mount Sinai
The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the seven member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to New York City’s large and diverse patient population.
The Icahn School of Medicine at Mount Sinai offers highly competitive MD, PhD, MD-PhD, and master’s degree programs, with enrollment of more than 1,200 students. It has the largest graduate medical education program in the country, with more than 2,600 clinical residents and fellows training throughout the Health System. Its Graduate School of Biomedical Sciences offers 13 degree-granting programs, conducts innovative basic and translational research, and trains more than 560 postdoctoral research fellows.
Ranked 11th nationwide in National Institutes of Health (NIH) funding, the Icahn School of Medicine at Mount Sinai is among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges. More than 4,500 scientists, educators, and clinicians work within and across dozens of academic departments and multidisciplinary institutes with an emphasis on translational research and therapeutics. Through Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai.
-------------------------------------------------------
* Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across seven hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 10 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2025-2026.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube.